Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 4 Issue 4, April 2005

In This Issue

Top of page ⤴

Editorial

Top of page ⤴

News

Top of page ⤴

News in Brief

Top of page ⤴

Patent Watch

Top of page ⤴

Patent Primer

  • Patent systems were designed to encourage and reward innovation. A system that prevents research into the subject matter covered by a patent would be inconsistent with such goals, and so the patent systems of most countries contain a provision that exempts from infringement experiments performed relating to the subject matter of a patent. In this article, the extent of the exclusion for experimental acts in Europe, particularly the UK, is discussed. I consider what constitutes an experimental act and to what extent the experimental use provision can effect scientific development.

    • Candi Soames
    Patent Primer
Top of page ⤴

An Audience With

  • The Senior Vice- President of Pfizer Global Research and Development discusses how recent setbacks for drug companies have changed their relationship with the public.

    An Audience With
Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Jean-Pierre J. Issa
    • Hagop M. Kantarjian
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Review Article

Top of page ⤴

Innovation

Top of page ⤴

Natureview

Top of page ⤴

Search

Quick links